Meeting
2017 ASCO Annual Meeting
Describing the value of the most common first line NSCLC regimens in a real world setting.
Authors
Lee N. Newcomer
UnitedHealth Group, Edina, MN
Lee N. Newcomer , Stacey DaCosta Byfield , Benjamin Chastek , Stephanie Korrer , Thomas Horstman , Jennifer Malin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 35, 2017 (suppl; abstr 9046)
DOI
10.1200/JCO.2017.35.15_suppl.9046
Abstract #
9046
Poster Bd #
372
Abstract Disclosures
Similar Posters
First Author: Domenico Galetta
Poster
2020 ASCO Virtual Scientific Program
Nintedanib + docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): Updated efficacy and safety results of the ongoing non-interventional study (NIS) VARGADO (NCT02392455).
First Author: Christian Grohé
Poster
2021 ASCO Annual Meeting
DREAM3R: Durvalumab with chemotherapy as first-line treatment in advanced pleural mesothelioma—A phase 3 randomized trial.
First Author: Patrick M. Forde
Poster
2019 ASCO Annual Meeting
Chemotherapy in KRAS-mutated chemotherapy naive non-small cell lung cancer patients: A phase III comparing cisplatin-pemetrexed with carboplatin-paclitaxel-bevacizumab: NVALT 22 (NCT02743923).
First Author: Anne-Marie C. Dingemans